Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Conavi Medical ( (TSE:CNVI) ) has shared an update.
Conavi Medical announced its fiscal Q2 2025 results, highlighting a significant $20 million financing led by U.S. institutional investors to support the development and commercial launch of its next-generation Novasight Hybrid System. The company is on track for a U.S. FDA 510(k) submission in Q3 2025, with the commercial launch expected in H1 2026. Recent updates in U.S. intracoronary imaging guidelines have validated the clinical utility of Conavi’s technology, positioning the company favorably in the market. Additionally, the company’s shares have been uplisted to the OTCQB, enhancing its visibility among U.S. investors.
More about Conavi Medical
Conavi Medical Corp. is a commercial-stage medical device company that specializes in designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures. The company focuses on developing innovative solutions like the Novasight Hybrid System to enhance interventional cardiology practices.
Average Trading Volume: 49,146
Technical Sentiment Signal: Sell
Current Market Cap: C$8.59M
Learn more about CNVI stock on TipRanks’ Stock Analysis page.